Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone

Abstract Background Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of immune checkpoint inhibition. Since bone metastases are not measurable l...

Full description

Bibliographic Details
Main Authors: Samuel Rosner, Filiz Sen, Michael Postow
Format: Article
Language:English
Published: BMJ Publishing Group 2017-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Myelophthisis
Melanoma
Bone marrow
Immune checkpoint inhibition
Pembrolizumab
PD-1 inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-017-0236-3

Internet

http://link.springer.com/article/10.1186/s40425-017-0236-3

Similar Items